A comparison of alprazolam with amitriptyline in the treatment of patients with neurotic or reactive depression

Banerji, Jaya; Brantingham, Patricia L.; McEwan, G. D.; Mason, John O.; Munt, D. F.; Renton, Robert; Scott, Aidan; Straková, Jarmila; Stevens, Victor J.

doi:10.1007/bf02943038

Cited by 9 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As for adverse reactions, a significantly greater number of side effects was reported in patients treated with TCA by Singh et al [38], whereas a comparable likelihood of reporting side effects was observed with both BZD and TCA in 3 other studies [35,37,39].…”

Section: Systematic Review Of Rct On the Efficacy Of Bzd In The Treatmentioning

confidence: 83%

“…Participants were assigned at random to the conditions in all studies, and all were double-blind trials. ITT analyses were performed in 8 reports [19,20,23,28,30,31,42,53], completers' data only were reported in 12 studies [25,27,29,37,39,41,44,45,47,49,50,54], and handling of attrition was not reported in 2 studies [46,48].…”

Section: Meta-analysis On the Efficacy Of Bzd In The Treatment Of Depmentioning

confidence: 99%

“…Seven reports directly compared BZD and TCA in patients suffering from mixed anxiety/ depressive states [34][35][36][37], neurotic depression [38,39], and DSM-III major depressive disorder with anxiety [40] (online suppl. Table 1).…”

Section: Systematic Review Of Rct On the Efficacy Of Bzd In The Treatmentioning

confidence: 99%

See 2 more Smart Citations

Benzodiazepines as a Monotherapy in Depressive Disorders: A Systematic Review

Benasi¹,

Guidi²,

Offidani³

et al. 2018

Psychother Psychosom

View full text Add to dashboard Cite

Background: The aim of this paper was to perform a systematic review and, when feasible, a meta-analysis of randomized controlled trials (RCT) which used benzodiazepines (BZD) as a monotherapy versus placebo, antidepressant drugs (AD), or both. Methods: Keyword searches were conducted for identifying RCT comparing BZD and AD, and/or placebo in the treatment of depression, using electronic databases from their inception up to April 2017. We selected reports of RCT in which BZD were compared to AD and/or placebo in the treatment of adult patients with a primary diagnosis of depressive disorder or anxious depression. When feasible, data were subjected to meta-analysis. Results: A total of 38 studies met the criteria for inclusion and were then included in the systematic review. Only 1 study concerned a newer AD, fluvoxamine. For the meta-analysis, we submitted data on response rate from 22 RCT, considering BZD versus placebo (8 comparisons) and BZD versus tricyclic antidepressants (TCA) (20 comparisons). There was a lack of significant differences as to response rate between BZD and placebo, as well as between BZD and TCA. Analysis of individual studies disclosed that, in more than half of the studies comparing BZD to TCA and/or placebo, BZD were significantly more effective than placebo and as effective as TCA. Conclusions: BZD are a therapeutic option in anxious depression and there are no indications that AD are preferable. There is a pressing need for RCT of adequate methodological quality and follow-up comparing BZD to second-generation AD and placebo in anxious depression.

show abstract

Section: Systematic Review Of Rct On the Efficacy Of Bzd In The Treatmentioning

confidence: 83%

Section: Meta-analysis On the Efficacy Of Bzd In The Treatment Of Depmentioning

confidence: 99%

See 1 more Smart Citation

Benzodiazepines as a Monotherapy in Depressive Disorders: A Systematic Review

Benasi¹,

Guidi²,

Offidani³

et al. 2018

Psychother Psychosom

View full text Add to dashboard Cite

show abstract

“…First-line treatments in depression are tricyclic antidepressants (TCAs). Clinical studies in depressed patients showed that alprazolam is at least equally effective as TCAs, such as amitriptyline (13,66,76,126,157,249), imipramine (84,86,87,180,212,277), dosulepine (41), desipramine (85,210), or doxepin (9). However, other studies reported that, although alprazolam provided symptom relief, amitriptyline (124,159,227) and imipramine (103,161) were significantly more effective.…”

Section: Depressionmentioning

confidence: 99%

Clinical Pharmacology, Clinical Efficacy, and Behavioral Toxicity of Alprazolam: A Review of the Literature

2004

View full text Add to dashboard Cite

Alprazolam is a benzodiazepine derivative that is currently used in the treatment of generalized anxiety, panic attacks with or without agoraphobia, and depression. Alprazolam has a fast onset of symptom relief (within the first week); it is unlikely to produce dependency or abuse. No tolerance to its therapeutic effect has been reported. At discontinuation of alprazolam treatment, withdrawal and rebound symptoms are common. Hence, alprazolam discontinuation must be tapered. An exhaustive review of the literature showed that alprazolam is significantly superior to placebo, and is at least equally effective in the relief of symptoms as tricyclic antidepressants (TCAs), such as imipramine. However, although alprazolam and imipramine are significantly more effective than placebo in the treatment of panic attacks, Selective Serotonin Reuptake Inhibitors (SSRIs) appear to be superior to either of the two drugs. Therefore, alprazolam is recommended as a second line treatment option, when SSRIs are not effective or well tolerated. In addition to its therapeutic effects, alprazolam produces adverse effects, such as drowsiness and sedation. Since alprazolam is widely used, many clinical studies investigated its cognitive and psychomotor effects. It is evident from these studies that alprazolam may impair performance in a variety of skills in healthy volunteers as well as in patients. Since the majority of alprazolam users are outpatients, this behavioral impairment limits the safe use of alprazolam in patients routinely engaged in potentially dangerous daily activities, such as driving a car.

show abstract

“…Это доказывалось результатами плацебоконтролируемых исследований [31][32][33]. Одновременно сравнительные двойные слепые исследования продемонстрировали, что алпразолам ослабляет проявления депрессий различной тяжести и генеза почти в той же степени, что и трициклические антидепрессанты [31,[34][35][36] (табл. 2).…”

unclassified

Depression therapy optimization at the present stage of development of psychopharmacology

Данилов¹

2013

Neurology, Neuropsychiatry, Psychosomatics

View full text Add to dashboard Cite

Д.С. Данилов Клиника психиатрии им. С.С. Корсакова УКБ № 3, НОКЦ «Психическое здоровье» ГБОУ ВПО «Первый МГМУ им. И.М. Сеченова» Минздрава России, Москва Представлены современные психофармакологические подходы к терапии депрессий. Обсуждается эффективность антидепрессантов с моноаминергическим механизмом действия. Рассматривается возможность применения комбинированной терапии антидепрессантами и препаратами других фармакологических групп. Отдельное внимание уделяется средствам, антидепрессивный эффект которых не связан с воздействием на моноаминергическую систему. Ключевые слова: антидепрессанты, механизм действия, депрессия, патогенез, ГАМКергические средства, алпразолам. Контакты: Дмитрий Сергеевич Данилов clinica2001@inbox.ru Depression therapy optimization at the present stage of development of psychopharmacologyThe paper presents current psychopharmacological approaches to therapy for depressions. It discusses the efficacy of depressants with a monoaminergic mechanism of action. Whether combination therapy with antidepressants and drugs from other pharmacological groups may be used is considered. Separate attention is paid to the agents whose antidepressant effect is unrelated to their action on the monoaminergic system. Оптимизация терапии депрессий на современном этапе развития психофармакологии И.В. Дамулин Кафедра нервных болезней ГБОУ ВПО «Первый МГМУ им. И.М. Сеченова» Минздрава России, Москва Рассматриваются клинические особенности и механизмы восстановления двигательных и когнитивных функций после перенесенного инсульта. Подчеркивается, что максимально ранняя терапия инсульта в немалой степени определяет успех проводимых в последующем реабилитационных мероприятий. Наиболее значительное восстановление наблюдается в первые 3 мес после развития инсульта, после 6 мес, как правило, возможно только незначительное улучшение. Однако у ряда больных процесс восстановления может продолжаться и более продолжительное время. Приводятся данные о применении препарата ницерголин (Сермион ® ) у данной категории больных. Ключевые слова: постинсультные нарушения, восстановление после инсульта, лечение, ницерголин. Контакты: Игорь Владимирович Дамулин igor_damulin@mtu-net.ru Heterogeneity of poststroke cognitive disorders: Diagnostic and therapeutic aspectsThe paper considers the clinical features and mechanisms of recovery of motor and cognitive functions after prior stroke. To treat stroke as soon as possible is emphasized to determine to a large extent the success of further rehabilitation measures. The most significant recovery is Гетерогенность постинсультных когнитивных нарушений: диагностические и терапевтические аспекты

show abstract

A comparison of alprazolam with amitriptyline in the treatment of patients with neurotic or reactive depression

Cited by 9 publications

References 5 publications

Benzodiazepines as a Monotherapy in Depressive Disorders: A Systematic Review

Benzodiazepines as a Monotherapy in Depressive Disorders: A Systematic Review

Clinical Pharmacology, Clinical Efficacy, and Behavioral Toxicity of Alprazolam: A Review of the Literature

Depression therapy optimization at the present stage of development of psychopharmacology

Contact Info

Product

Resources

About